SION vs DMRC Comparison

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers, and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.